Severe acute respiratory syndrome coronavirus 2. Severe acute respiratory syndrome coronavirus 2

The vaccine SarsCov2 Immunogem, developed in this work uses peptide biomolecules marked with antigens, which will prepare the immune system against a possible invasion. These Nanoparticles can induce an immune response and activate T cells (white blood cells) without the use of additional adjuvants, which are responsible for causing inflammation in some people, and which are associated with common side effects of vaccines, such as pain at the injection site or low fever.Studies have shown that peptide compounds, within a specific construction context, generate a strong immune response through the intranasal route.Studies also point out that the methodology of using the nasal vaccine as a form of immunization has the potential to be more effective and with fewer side effects.I performed a complete analysis of the mRNA sequence that constitutes the viral genome, using bioinformatics tools and methodology prepared within the protein structure. Thus, it was possible to determine an affinity of the peptide composed of 22 amino acids to generate a rapid and adequate immune response convenient for the production of a vaccine with great specificity for Covid-19.The main characteristic of this work is to offer an immunogen with a short and well-defined molecular structure but with excellent antigenicity in a region where the virus cannot undergo changes strains.